ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics Provides 2023 Outlook

06 Jan 2023 07:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

29 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Key Leadership Transitions

22 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

10 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

08 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

27 Sep 2022 07:00:24 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

30 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

03 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Expands Leadership Team

27 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference

01 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

16 May 2022 07:00:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

10 May 2022 07:00:02 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

03 May 2022 07:00:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

24 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

02 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Expands Leadership Team

01 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Provides R&D Update

11 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

27 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

03 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

18 Nov 2021 16:01:00 By Nasdaq GlobeNewswire